Kabir Nath: Our Mission, Progress and Future Perspectives Post published:January 31, 2023 Post category:2022 Year in Review
Late-Stage Psychedelic Trials: A brief review of the two most mature psychedelic drug development programs Post published:January 30, 2023 Post category:2022 Year in Review
Doing Things Differently: Beyond Business as Usual in the Psychedelics Space Post published:January 27, 2023 Post category:2022 Year in Review
Adelaide Wilcox King: The Psychedelic Industry as a Catalyst for Reimagining Capitalism and the Purpose-Driven Firm Post published:January 27, 2023 Post category:2022 Year in Review
Julia Mande: Consider the Conditions: Growing a Psychedelic Ecosystem Post published:January 27, 2023 Post category:2022 Year in Review
Adapting to the Squeeze: Spending Trends, Slimming Pipelines, M&A and Partnerships in 2022 Post published:January 26, 2023 Post category:2022 Year in Review
Psychedelic Investor Pulse Survey – Q4 2022 Post published:January 26, 2023 Post category:2022 Year in Review
Panel: Three Psychedelics Companies that Raised in 2022 Post published:January 24, 2023 Post category:2022 Year in Review
Panel: Psychedelic VCs Reflect on 2022 Post published:January 24, 2023 Post category:2022 Year in Review